Defactinib is a CYP3A4 substrate. Concomitant use of defactinib with a strong CYP3A4 inhibitor increases defactinib exposure [see Clinical Pharmacology (12.3) ], which may increase the risk of AVMAPKI FAKZYNJA CO-PACK adverse reactions. Defactinib is a CYP3A4 substrate.
Source: FDA drug label - avutometinib potassium and defactinib hydrochloride